Date: 10th December 2019
Time: 14:00 - 15:30
Speakers: PSI/EFSPI SIG Quantitative Decision-Making members:
Pierre Colin (Sanofi)
Juan Abellan (GSK)
Gaëlle Saint-Hilary (Servier)
Quantitative methods to support decision-making in clinical drug development already exist, but may be unknown or unused by pharmaceutical companies. We performed a survey among pharmaceutical companies, targeting people with different profiles (statisticians, non-statisticians and decision-makers) working at different stages of the clinical development (study level, development level or portfolio level). This survey allowed us to analyze which quantitative methods are known, which quantitative methods are used (or not), what benefit is expected from this kind of methods, and what are the needs for a larger use of quantitative methods to support decision-making. It permitted to understand the gaps and some of the issues associated to the use of such methods in drug development. The webinars are intended to share the learnings from the survey and to promote different quantitative methods for decision-making.
Registration: To register for this free webinar, please click here.
Date: 10th December 2019
Time: 14:00 - 15:30
Speakers: PSI/EFSPI SIG Quantitative Decision-Making members:
Pierre Colin (Sanofi)
Juan Abellan (GSK)
Gaëlle Saint-Hilary (Servier)
Quantitative methods to support decision-making in clinical drug development already exist, but may be unknown or unused by pharmaceutical companies. We performed a survey among pharmaceutical companies, targeting people with different profiles (statisticians, non-statisticians and decision-makers) working at different stages of the clinical development (study level, development level or portfolio level). This survey allowed us to analyze which quantitative methods are known, which quantitative methods are used (or not), what benefit is expected from this kind of methods, and what are the needs for a larger use of quantitative methods to support decision-making. It permitted to understand the gaps and some of the issues associated to the use of such methods in drug development. The webinars are intended to share the learnings from the survey and to promote different quantitative methods for decision-making.
Registration: To register for this free webinar, please click here.
Date: 10th December 2019
Time: 14:00 - 15:30
Speakers: PSI/EFSPI SIG Quantitative Decision-Making members:
Pierre Colin (Sanofi)
Juan Abellan (GSK)
Gaëlle Saint-Hilary (Servier)
Quantitative methods to support decision-making in clinical drug development already exist, but may be unknown or unused by pharmaceutical companies. We performed a survey among pharmaceutical companies, targeting people with different profiles (statisticians, non-statisticians and decision-makers) working at different stages of the clinical development (study level, development level or portfolio level). This survey allowed us to analyze which quantitative methods are known, which quantitative methods are used (or not), what benefit is expected from this kind of methods, and what are the needs for a larger use of quantitative methods to support decision-making. It permitted to understand the gaps and some of the issues associated to the use of such methods in drug development. The webinars are intended to share the learnings from the survey and to promote different quantitative methods for decision-making.
Registration: To register for this free webinar, please click here.
Date: 10th December 2019
Time: 14:00 - 15:30
Speakers: PSI/EFSPI SIG Quantitative Decision-Making members:
Pierre Colin (Sanofi)
Juan Abellan (GSK)
Gaëlle Saint-Hilary (Servier)
Quantitative methods to support decision-making in clinical drug development already exist, but may be unknown or unused by pharmaceutical companies. We performed a survey among pharmaceutical companies, targeting people with different profiles (statisticians, non-statisticians and decision-makers) working at different stages of the clinical development (study level, development level or portfolio level). This survey allowed us to analyze which quantitative methods are known, which quantitative methods are used (or not), what benefit is expected from this kind of methods, and what are the needs for a larger use of quantitative methods to support decision-making. It permitted to understand the gaps and some of the issues associated to the use of such methods in drug development. The webinars are intended to share the learnings from the survey and to promote different quantitative methods for decision-making.
Registration: To register for this free webinar, please click here.
Date: 10th December 2019
Time: 14:00 - 15:30
Speakers: PSI/EFSPI SIG Quantitative Decision-Making members:
Pierre Colin (Sanofi)
Juan Abellan (GSK)
Gaëlle Saint-Hilary (Servier)
Quantitative methods to support decision-making in clinical drug development already exist, but may be unknown or unused by pharmaceutical companies. We performed a survey among pharmaceutical companies, targeting people with different profiles (statisticians, non-statisticians and decision-makers) working at different stages of the clinical development (study level, development level or portfolio level). This survey allowed us to analyze which quantitative methods are known, which quantitative methods are used (or not), what benefit is expected from this kind of methods, and what are the needs for a larger use of quantitative methods to support decision-making. It permitted to understand the gaps and some of the issues associated to the use of such methods in drug development. The webinars are intended to share the learnings from the survey and to promote different quantitative methods for decision-making.
Registration: To register for this free webinar, please click here.
Date: 10th December 2019
Time: 14:00 - 15:30
Speakers: PSI/EFSPI SIG Quantitative Decision-Making members:
Pierre Colin (Sanofi)
Juan Abellan (GSK)
Gaëlle Saint-Hilary (Servier)
Quantitative methods to support decision-making in clinical drug development already exist, but may be unknown or unused by pharmaceutical companies. We performed a survey among pharmaceutical companies, targeting people with different profiles (statisticians, non-statisticians and decision-makers) working at different stages of the clinical development (study level, development level or portfolio level). This survey allowed us to analyze which quantitative methods are known, which quantitative methods are used (or not), what benefit is expected from this kind of methods, and what are the needs for a larger use of quantitative methods to support decision-making. It permitted to understand the gaps and some of the issues associated to the use of such methods in drug development. The webinars are intended to share the learnings from the survey and to promote different quantitative methods for decision-making.
Registration: To register for this free webinar, please click here.
PSI Training Course: Regulatory Guidelines for Statisticians
Dates: Wednesday 2nd & Thursday 3rd October 2024
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Efficient R&D: SVEM and Advanced DOE in Preclinical Toxicity Testing
Date: Tuesday 8th October 2024
This 1-hour webinar will be an opportunity to hear how JMP have been influential in the toxicity testing of an oncology formulation in a pre-clinical setting. At the end of the presentation there will also be the opportunity to ask questions.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Date: The Second Wednesday of every Month
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
Joint PSI/EFSPI Small Populations & RWD SIG Webinar: Harnessing Real-World Data (RWD) in clinical trials for small populations and rare diseases
Date: Thursday 17th October 2024
In this webinar we will review the range of statistical methodologies used to harness the potential of Real-World Data (RWD) in clinical development, particularly in the context of rare diseases and small populations like paediatrics. The session will include theoretical understanding and practical case studies, with a special focus on Bayesian methods and causal inference.
Date: Wednesday 23rd October 2024
In this event, we’ll start with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A.
PSI Training Course: Introduction to Bayesian Methods
Dates:
Module 1 - Wednesday 20th November
Module 2 - Tuesday 26th November
Module 3 - Thursday 28th November
This interactive and hands on online course, aimed at beginner Bayesians who have little or no experience in Bayesian statistics, is split into 3 modules. Module 1 introduces Bayesian concepts and looks at how Bayes has been used recently in the Pharmaceutical Industry, and participants will undertake their own data collection exercise in order to analyse a simple Bayesian trial. Module 2 takes a look at the concepts of Bayesian statistics and key terminology and provides a chance to analyse some data using a simple Bayesian approach. Module 3 takes a further look at the use of Bayesian statistics in drug development and regulatory requirements and digs deeper into analysis issues.
Date: 20 October 2024
This event is aimed at students with an interest in the field of Medical Statistics, for example within pharmaceuticals, healthcare and/or medical research.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Date: Re-scheduled to Tuesday 26th November 2024
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
Date: Tuesday 10th December 2024
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
Date: October 2024 - July 2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
Senior Medical Statistician & Statistical Programmer
An exciting opportunity has arisen for a Senior Medical Statistician & Statistical Programmer to join the UKCRC fully registered Derby Clinical Trials Support Unit (Derby CTSU).